Immunovant, Inc. (NASDAQ:IMVT - Free Report) - Equities research analysts at Zacks Research lifted their FY2024 EPS estimates for shares of Immunovant in a research report issued to clients and investors on Thursday, April 25th. Zacks Research analyst E. Bagri now forecasts that the company will post earnings per share of ($1.72) for the year, up from their prior estimate of ($1.73). The consensus estimate for Immunovant's current full-year earnings is ($1.70) per share. Zacks Research also issued estimates for Immunovant's Q4 2024 earnings at ($0.44) EPS, Q1 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.04) EPS, Q1 2026 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.52) EPS and FY2026 earnings at ($1.91) EPS.
Other equities analysts have also issued reports about the stock. Truist Financial reaffirmed a "buy" rating and set a $48.00 target price on shares of Immunovant in a report on Monday, March 25th. Wolfe Research began coverage on shares of Immunovant in a research report on Thursday, February 15th. They issued an "outperform" rating and a $55.00 price objective for the company. Oppenheimer initiated coverage on shares of Immunovant in a research note on Thursday, March 28th. They set an "outperform" rating and a $50.00 target price on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Immunovant in a research report on Friday, January 12th. Finally, JPMorgan Chase & Co. started coverage on Immunovant in a research report on Tuesday, February 20th. They set an "overweight" rating and a $51.00 target price on the stock. Seventeen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $48.00.
Check Out Our Latest Analysis on IMVT
Immunovant Stock Up 1.2 %
Shares of IMVT traded up $0.32 during mid-day trading on Monday, reaching $27.49. The company had a trading volume of 1,566,447 shares, compared to its average volume of 1,228,447. Immunovant has a 52-week low of $16.58 and a 52-week high of $45.58. The stock has a 50 day moving average of $31.90 and a two-hundred day moving average of $35.72. The stock has a market capitalization of $3.99 billion, a P/E ratio of -14.94 and a beta of 0.65.
Immunovant (NASDAQ:IMVT - Get Free Report) last released its quarterly earnings data on Monday, February 12th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07.
Insider Activity
In related news, insider Mark S. Levine sold 2,134 shares of the firm's stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $36.15, for a total transaction of $77,144.10. Following the completion of the sale, the insider now directly owns 301,968 shares of the company's stock, valued at approximately $10,916,143.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Immunovant news, CFO Eva Renee Barnett sold 2,930 shares of the business's stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $36.15, for a total value of $105,919.50. Following the sale, the chief financial officer now owns 320,420 shares of the company's stock, valued at $11,583,183. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Mark S. Levine sold 2,134 shares of the company's stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $36.15, for a total value of $77,144.10. Following the transaction, the insider now owns 301,968 shares in the company, valued at $10,916,143.20. The disclosure for this sale can be found here. Insiders have sold a total of 81,560 shares of company stock valued at $2,424,601 in the last quarter. Insiders own 4.80% of the company's stock.
Institutional Investors Weigh In On Immunovant
A number of institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. boosted its holdings in Immunovant by 32.4% during the 1st quarter. Principal Financial Group Inc. now owns 582,721 shares of the company's stock valued at $18,828,000 after acquiring an additional 142,606 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Immunovant by 66.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 27,936 shares of the company's stock worth $903,000 after purchasing an additional 11,202 shares in the last quarter. WCM Investment Management LLC lifted its position in shares of Immunovant by 58.0% during the first quarter. WCM Investment Management LLC now owns 169,665 shares of the company's stock worth $5,482,000 after purchasing an additional 62,264 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Immunovant by 51.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 65,091 shares of the company's stock valued at $2,103,000 after purchasing an additional 22,226 shares during the period. Finally, Los Angeles Capital Management LLC grew its holdings in shares of Immunovant by 185.4% in the first quarter. Los Angeles Capital Management LLC now owns 14,371 shares of the company's stock valued at $464,000 after purchasing an additional 9,335 shares in the last quarter. 47.08% of the stock is owned by institutional investors and hedge funds.
Immunovant Company Profile
(
Get Free Report)
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
Further Reading
Before you consider Immunovant, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunovant wasn't on the list.
While Immunovant currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
